{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:29:20Z","timestamp":1787110160520,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105505","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:01:16Z","timestamp":1785283276000},"page":"105505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group"],"prefix":"10.1016","volume":"225","author":[{"given":"J\u00e9r\u00e9my","family":"Mercier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cornillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Fontugne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Guimas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa","family":"Bouleftour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Ollivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raafet","family":"Affi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Pouessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Culine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-5220","authenticated-orcid":false,"given":"Fabien","family":"Moinard-Butot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105505_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259272","article-title":"Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: a retrospective exploratory study","volume":"16","author":"Al-Ezzi","year":"2021","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105505_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER Trial","volume":"211","author":"Allory","year":"2024","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1200\/JCO.2024.42.4_suppl.624","article-title":"PEMBROBLAD: real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants","volume":"42","author":"Amrane","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105505_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib6","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000534858","article-title":"Metastatic squamous cell carcinoma of the urinary bladder: urgent call for new therapies","volume":"108","author":"Banek","year":"2024","journal-title":"Urol. Int."},{"key":"10.1016\/j.critrevonc.2026.105505_bib8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib9","doi-asserted-by":"crossref","first-page":"S1211","DOI":"10.1016\/j.annonc.2023.09.1028","article-title":"2379P AVENANCE: Subgroup analysis of patients (pts) with advanced urothelial carcinoma (aUC) with histological variants from a real-world (RW) study of avelumab first-line maintenance (1LM)","volume":"34","author":"Barthelemy","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in france: overall results from the noninterventional avenance study and analysis of outcomes by second-line treatment","volume":"8","author":"Barth\u00e9l\u00e9my","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2016.06.007","article-title":"Human epidermal growth factor receptor 2 overexpression in micropapillary and other variants of urothelial carcinoma","volume":"4","author":"Behzato\u011flu","year":"2018","journal-title":"Eur. Urol. Focus."},{"key":"10.1016\/j.critrevonc.2026.105505_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib14","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31952","article-title":"Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?","volume":"125","author":"Berg","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105505_bib15","first-page":"1129","article-title":"Les Traitements des tumeurs rares de la vessie","volume":"12","author":"Bouchot","year":"2002","journal-title":"Progr\u00e8S. En. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.canrad.2023.07.018","article-title":"[Does radiation therapy for prostate cancer increase the risk of second cancers?]","volume":"28","author":"Bou\u00e9-Rafl\u00e9","year":"2024","journal-title":"Cancer Radiother."},{"key":"10.1016\/j.critrevonc.2026.105505_bib17","doi-asserted-by":"crossref","first-page":"117.e17","DOI":"10.1016\/j.urolonc.2024.01.002","article-title":"The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: data from the International Robotic Cystectomy Consortium","volume":"42","author":"Cooke","year":"2024","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.urolonc.2011.01.008","article-title":"A prospective randomized trial for postoperative vs. preoperative adjuvant radiotherapy for muscle-invasive bladder cancer","volume":"31","author":"El-Monim","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.671969","article-title":"Treatments outcomes in histological variants and non-urothelial bladder cancer: results of a multicenter retrospective study","volume":"11","author":"Epaillard","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib20","unstructured":"EvolveImmune United, Inc, 2025. A Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas (Clinical trial registration No. NCT07217171). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105505_bib21","first-page":"421","article-title":"The changing patterns of bladder cancer in Egypt over the past 26 years","volume":"19","author":"Felix","year":"2008","journal-title":"Cancer Causes Control."},{"key":"10.1016\/j.critrevonc.2026.105505_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18203\/2349-3933.ijam20251942","article-title":"Long-term indwelling urinary catheterization and bladder cancer","volume":"12","author":"Fitra","year":"2025","journal-title":"Int. J. Adv. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/modpathol.3801001","article-title":"TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity","volume":"21","author":"Fong","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.urology.2006.10.029","article-title":"Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract","volume":"69","author":"Galsky","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105505_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102273","article-title":"Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials","volume":"23","author":"Giannatempo","year":"2025","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105505_bib26","first-page":"211","article-title":"Comparative study of conventional urothelial carcinoma, squamous differentiation carcinoma and pure squamous carcinoma in patients with invasive bladder tumors","volume":"7","author":"Gluck","year":"2014","journal-title":"J. Med. Life"},{"key":"10.1016\/j.critrevonc.2026.105505_bib27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urology.2020.06.065","article-title":"Squamous Cell Carcinoma of the Bladder Is Not Associated With High-risk HPV","volume":"144","author":"Gordetsky","year":"2020","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105505_bib28","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib31","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.purol.2022.04.009","volume":"32","author":"Hentzen","year":"2022","journal-title":"Progr\u00e8S. En. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdz296","article-title":"EAU\u2013ESMO consensus statements on the management of advanced and variant bladder cancer\u2014an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","volume":"30","author":"Horwich","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib35","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2001.19.9.2527","article-title":"Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer","volume":"19","author":"Hussain","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib36","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105505_bib37","article-title":"Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study","volume":"S0302-2838","author":"Jindal","year":"2025","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12885-023-10576-0","article-title":"Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer","volume":"23","author":"Jung","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105505_bib39","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clgc.2014.04.002","article-title":"Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation","volume":"12","author":"Khaled","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105505_bib40","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/jso.27525","article-title":"Squamous cell carcinoma of the bladder: Demographics and outcomes associated with surgery and radiotherapy","volume":"129","author":"Larkins","year":"2024","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib41","series-title":"in: StatPearls","article-title":"Bladder Cancer","author":"Leslie","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105505_bib42","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.critrevonc.2019.01.008","article-title":"Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review","volume":"135","author":"Maia","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1308\/rcsann.2016.0343","article-title":"Risk factors for development of primary bladder squamous cell carcinoma","volume":"99","author":"Manley","year":"2017","journal-title":"Ann. R. Coll. Surg. Engl."},{"key":"10.1016\/j.critrevonc.2026.105505_bib45","doi-asserted-by":"crossref","first-page":"353.e17","DOI":"10.1016\/j.urolonc.2019.01.020","article-title":"The impact of squamous histology on survival in patients with muscle-invasive bladder cancer","volume":"37","author":"Matulay","year":"2019","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11912-018-0727-5","article-title":"Molecular Subtypes of Bladder Cancer","volume":"20","author":"McConkey","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105505_bib47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib48","first-page":"260","article-title":"Chronic inflammation and bladder cancer","volume":"25","author":"Michaud","year":"2007","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2026.105505_bib49","first-page":"4465","article-title":"Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report","volume":"31","author":"Miyata","year":"2011","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.critrevonc.2026.105505_bib50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.5_suppl.722","article-title":"Real world effectiveness of systemic treatment in patients (pts) with advanced upper tract urothelial carcinoma (UTUC) with histological variants","volume":"43","author":"Moinard-Butot","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105505_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00262-026-04328-9","article-title":"Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV)","volume":"75","author":"Mollica","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105505_bib52","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-5347(17)67849-2","article-title":"Potentialities of bladder epithelium","volume":"71","author":"Mostofi","year":"1954","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib53","unstructured":"National Cancer Institute (NCI), 2025a. A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder\/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer (Clinical trial registration No. NCT06161532). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105505_bib54","unstructured":"National Cancer Institute (NCI), 2025b. A Phase II Multicenter Study of Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (Clinical trial registration No. NCT06041503). clinicaltrials.gov."},{"key":"10.1016\/j.critrevonc.2026.105505_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib56","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib57","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/ijc.32842","article-title":"Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case-control study","volume":"146","author":"Potteg\u00e5rd","year":"2020","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105505_bib58","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. oncol. : off. j. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib59","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib60","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib61","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105505_bib62","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"S0923-7534","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib63","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0360-3016(86)90377-9","article-title":"Radiotherapy for squamous carcinoma of the urinary bladder","volume":"12","author":"Quilty","year":"1986","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105505_bib65","article-title":"News in the classification of WHO 2022 bladder tumors","author":"Raspollini","year":"2023","journal-title":"Pathologica 115 3240"},{"key":"10.1016\/j.critrevonc.2026.105505_bib66","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.3390\/cancers14184411","article-title":"Expression of Nectin-4 in Variant Histologies of Bladder Cancer and Its Prognostic Value-Need for Biomarker Testing in High-Risk Patients?","volume":"14","author":"Rodler","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105505_bib67","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib68","article-title":"French AFU Cancer Committee Guidelines - Update 2024-2026: Muscle-invasive bladder cancer (MIBC)","volume":"34","author":"Roumigui\u00e9","year":"2024","journal-title":"Fr. J. Urol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib69","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/cam4.3699","article-title":"A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract","volume":"10","author":"Sarfaty","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib71","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0090-4295(86)90006-3","article-title":"Squamous cell carcinoma of bladder: an increased incidence in blacks","volume":"28","author":"Schroder","year":"1986","journal-title":"Urology"},{"key":"10.1016\/j.critrevonc.2026.105505_bib72","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1464-410X.2011.10582.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/j.critrevonc.2026.105505_bib73","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2\u2013Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib74","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug. Deliv."},{"key":"10.1016\/j.critrevonc.2026.105505_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clgc.2020.06.004","article-title":"Role of Neoadjuvant Chemotherapy in Squamous Variant Histology in Urothelial Bladder Cancer: Does Presence and Percentage Matter?","volume":"19","author":"Speir","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105505_bib76","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest. New. Drugs"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105505_bib77","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib78","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105505_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111682","article-title":"Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2026.105505_bib80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2011201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105505_bib81","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.ijrobp.2019.06.131","article-title":"Randomized Trial of Adjuvant Therapies after Radical Cystectomy for Locally Advanced Bladder Cancer: Squamous Cell Carcinoma Subgroup Analysis","volume":"105","author":"Zaghloul","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2026.105505_bib82","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00345-020-03362-1","article-title":"Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent","volume":"39","author":"Zamboni","year":"2021","journal-title":"World J. Urol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003926?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003926?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:57:03Z","timestamp":1787108223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":82,"alternative-id":["S1040842826003926"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105505","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Squamous cell carcinoma of the bladder: Current evidence, therapeutic challenges, and research perspectives from the French AVENTUR group","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105505"}}